BaroFold Licences PreEMT Technology To Nuron Biotech
BaroFold has entered into an agreement to exclusively license its PreEMT Technology to Nuron Biotech for the development of BaroFeron and follow-on interferon beta products.
BaroFeron is a proprietary recombinant human interferon beta being developed for the treatment of multiple sclerosis.
Matthew Brewer, president and CEO of BaroFold, said: “BaroFeron is an optimised, aggregate-free version of interferon beta-1b created by applying BaroFold’s PreEMT high pressure protein disaggregation and refolding technology.
“BaroFeron’s proprietary and improved structure may result in reduced immune responses compared to other interferon beta products. The application of PreEMT in developing BaroFeron and the promising Phase 1 clinical data serve as positive validation for PreEMT.
“Further, this transaction demonstrates BaroFold’s strategic business focus on leveraging PreEMT as the technology of choice to support its industry partners’ efforts to create novel protein therapeutics, manufacture follow-on biologics and conduct life-cycle management of protein therapeutics.”
Shankar Musunuri, CEO of Nuron, said: “BaroFeron exemplifies Nuron’s focus on developing and commercializing biotherapeutics with enhanced product profiles. We are currently developing the clinical and regulatory strategy for advanced clinical trials of BaroFeron and look forward to advancing this exciting candidate.”